Profiling of Phospho-AKT, Phospho-mTOR, Phospho-MAPK and EGFR in Non-small Cell Lung Cancer

Journal of Histochemistry and Cytochemistry

Volumn 62, Issue 5, 2014, Pages 335-346

  Kitano, Haruhisa ^a,b,d   Chung, Joon Yong ^a   Ylaya, Kris ^a   Conway, Catherine ^a   Takikita, Mikiko ^e   Fukuoka, Junya ^b   Doki, Yoshinori ^c   Hanaoka, Jun ^d   Hewitt, Stephen M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TOYAMA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e NONE

Author keywords

AKT; EGFR; Image analysis; Immunohistochemistry; MAPK; mTOR; Non small cell lung cancer; Survival analysis; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SMOKING; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

AKT; EGFR; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAPK; MTOR; NON-SMALL CELL LUNG CANCER; SURVIVAL ANALYSIS; TISSUE MICROARRAY;

AGED; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CLUSTER ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 84899682848     PISSN: 00221554     EISSN: 15515044     Source Type: Journal    
DOI: 10.1369/0022155414523022     Document Type: Article

References (66)

1. Akinleye A,Furqan M,Mukhi N,Ravella P,Liu D.MEK and the inhibitors: from bench to bedside.J Hematol Oncol. 2013;6:27.
2. Al-Bazz YO,Underwood JC,Brown BL,Dobson PR.Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer.Eur J Cancer. 2009;45:694-704.
3. Cappuzzo F,Gregorc V,Rossi E,Cancellieri A,Magrini E,Paties CT,Ceresoli G,Lombardo L,Bartolini S,Calandri C,de Rosa M,Villa E,Crino L.Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.J Clin Oncol. 2003;21:2658-2663.
4. Cappuzzo F,Ligorio C,Jänne PA,Toschi L,Rossi E,Trisolini R,Paioli D,Holmes AJ,Magrini E,Finocchiaro G,Bartolini S,Cancellieri A,Ciardiello F,Patelli M,Crino L,Varella-Garcia M.Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.J Clin Oncol. 2007;25:2248-2255.
5. Cappuzzo F,Magrini E,Ceresoli GL,Bartolini S,Rossi E,Ludovini V,Gregorc V,Ligorio C,Cancellieri A,Damiani S,Spreafico A,Paties CT,Lombardo L,Calandri C,Bellezza G,Tonato M,Crinò L.Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.J Natl Cancer Inst. 2004;96:1133-1141.
6. Chung JY,Hong SM,Choi BY,Cho H,Yu E,Hewitt SM.The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma.Clin Cancer Res. 2009;15:660-667.
7. Chung JY,Kitano H,Takikita M,Cho H,Noh KH,Kim TW,Ylaya K,Hanaoka J,Fukuoka J,Hewitt SM.Synaptonemal complex protein 3 as a novel prognostic marker in early stage non-small cell lung cancer.Hum Pathol. 2012;44:472-479.
8. Dai B,Yoo SY,Bartholomeusz G,Graham RA,Majidi M,Yan S,Meng J,Ji L,Coombes K,Minna JD,Fang B,Roth JA.KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.Cancer Res. 2013;73:5532-5543.
9. De Luca A,Maiello MR,D'Alessio A,Pergameno M,Normanno N.The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.Expert Opin Ther Targets. 2012;16:S17-27.
10. Donev IS,Wang W,Yamada T,Li Q,Takeuchi S,Matsumoto K,Yamori T,Nishioka Y,Sone S,Yano S.Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.Clin Cancer Res. 2011;17:2260-2269.
11. Easton JB,Houghton PJ.Therapeutic potential of target of rapamycin inhibitors.Expert Opin Ther Targets. 2004;8:551-564.
12. Engelman JA,Chen L,Tan X,Crosby K,Guimaraes AR,Upadhyay R,Maira M,McNamara K,Perera SA,Song Y,Chirieac LR,Kaur R,Lightbown A,Simendinger J,Li T,Padera RF,García-Echeverría C,Weissleder R,Mahmood U,Cantley LC,Wong KK.Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.Nat Med. 2008;14:1351-1356.
13. Farris AB,Adams CD,Brousaides N,Della Pelle PA,Collins AB,Moradi E,Smith RN,Grimm PC,Colvin RB.Morphometric and visual evaluation of fibrosis in renal biopsies.J Am Soc Nephrol. 2011;22:176-186.
14. Fasolo A,Sessa C.mTOR inhibitors in the treatment of cancer.Expert Opin Investig Drugs. 2008;17:1717-1734.
15. Franke TF,Kaplan DR,Cantley LC.PI3K: downstream AKTion blocks apoptosis.Cell. 1997;88:435-437.
16. Fukuoka J,Fujii T,Shih JH,Dracheva T,Meerzaman D,Player A,Hong K,Settnek S,Gupta A,Buetow K,Hewitt S,Travis WD,Jen J.Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.Clin Cancer Res. 2004;10:4314-4324.
17. Galleges Ruiz MI,Floor K,Steinberg SM,Grunberg K,Thunnissen FB,Belien JA,Meijer GA,Peters GJ,Smit EF,Rodriguez JA,Giaccone G.Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.Br J Cancer. 2009;100:145-152.
18. Gharbi SI,Zvelebil MJ,Shuttleworth SJ,Hancox T,Saghir N,Timms JF,Waterfield MD.Exploring the specificity of the PI3K family inhibitor LY294002.Biochem J. 2007;404:15-21.
19. Guo RX,Qiao YH,Zhou Y,Li LX,Shi HR,Chen KS.Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.Pathol Int. 2008;58:749-756.
20. Hager M,Haufe H,Kemmerling R,Hitzl W,Mikuz G,Moser PL,Kolbitsch C.Increased Activated Akt Expression in Renal Cell Carcinomas and Prognosis.J Cell Mol Med. 2009;13:2181-2188.
21. Han SW,Kim TY,Hwang PG,Jeong S,Kim J,Choi IS,Oh DY,Kim JH,Kim DW,Chung DH,Im SA,Kim YT,Lee JS,Heo DS,Bang YJ,Kim NK.Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.J Clin Oncol. 2005;23:2493-2501.
22. Herberger B,Puhalla H,Lehnert M,Wrba F,Novak S,Brandstetter A,Gruenberger B,Gruenberger T,Pirker R,Filipits M.Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma.Clin Cancer Res. 2007;13:4795-4799.
23. Hewitt SM,Badve SS,True LD.Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy.Clin Cancer Res. 2012;18:1524-1530.
24. Hoeflich KP,O'Brien C,Boyd Z,Cavet G,Guerrero S,Jung K,Januario T,Savage H,Punnoose E,Truong T,Zhou W,Berry L,Murray L,Amler L,Belvin M,Friedman LS,Lackner MR.In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.Clin Cancer Res. 2009;15:4649-4664.
25. Holt SV,Logie A,Davies BR,Alferez D,Runswick S,Fenton S,Chresta CM,Gu Y,Zhang J,Wu YL,Wilkinson RW,Guichard SM,Smith PD.Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).Cancer Res. 2012;72:1804-1813.
26. Hosokawa S,Toyooka S,Fujiwara Y,Tokumo M,Soh J,Takigawa N,Hotta K,Yoshino T,Date H,Tanimoto M,Kiura K.Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.Lung Cancer. 2009;66:107-113.
27. Howard BA,Zheng Z,Campa MJ,Wang MZ,Sharma A,Haura E,Herndon JE,Fitzgerald MC,Bepler G,Patz EF.Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.Lung Cancer. 2004;46:313-323.
28. Janmaat ML,Kruyt FA,Rodriguez JA,Giaccone G.Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.Clin Cancer Res. 2003;9:2316-2326.
29. Jokinen E,Laurila N,Koivunen JP.Alternative dosing of dual PI3K and MEK inhibition in cancer therapy.BMC Cancer. 2012;12:612.
30. Jorissen RN,Walker F,Pouliot N,Garrett TP,Ward CW,Burgess AW.Epidermal growth factor receptor: mechanisms of activation and signalling.Exp Cell Res. 2003;284:31-53.
31. Kitano H,Kageyama S,Hewitt SM,Hayashi R,Doki Y,Ozaki Y,Fujino S,Takikita M,Kubo H,Fukuoka J.Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival.Arch Pathol Lab Med. 2010;134:1520-1527.
32. Kononen J,Bubendorf L,Kallioniemi A,Barlund M,Schraml P,Leighton S,Torhorst J,Mihatsch MJ,Sauter G,Kallioniemi OP.Tissue microarrays for high-throughput molecular profiling of tumor specimens.Nat Med. 1998;4:844-847.
33. Krishnan K,Bruce B,Hewitt S,Thomas D,Khanna C,Helman LJ.Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway.Clin Exp Metastasis. 2006;23:227-236.
34. Legrier ME,Yang CP,Yan HG,Lopez-Barcons L,Keller SM,Perez-Soler R,Horwitz SB,McDaid HM.Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.Cancer Res. 2007;67:11300-11308.
35. Lim WT,Zhang WH,Miller CR,Watters JW,Gao F,Viswanathan A,Govindan R,McLeod HL.PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.Oncol Rep. 2007;17:853-857.
36. LoPiccolo J,Blumenthal GM,Bernstein WB,Dennis PA.Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.Drug Resist Updat. 2008;11:32-50.
37. Lorusso PM,Adjei AA,Varterasian M,Gadgeel S,Reid J,Mitchell DY,Hanson L,DeLuca P,Bruzek L,Piens J,Asbury P,Van Becelaere K,Herrera R,Sebolt-Leopold J,Meyer MB.Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.J Clin Oncol. 2005;23:5281-5293.
38. Massion PP,Taflan PM,Shyr Y,Rahman SM,Yildiz P,Shakthour B,Edgerton ME,Ninan M,Andersen JJ,Gonzalez AL.Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.Am J Respir Crit Care Med. 2004;170:1088-1094.
39. Molinolo AA,Hewitt SM,Amornphimoltham P,Keelawat S,Rangdaeng S,Meneses García A,Raimondi AR,Jufe R,Itoiz M,Gao Y,Saranath D,Kaleebi GS,Yoo GH,Leak L,Myers EM,Shintani S,Wong D,Massey HD,Yeudall WA,Lonardo F,Ensley J,Gutkind JS.Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.Clin Cancer Res. 2007;13:4964-4973.
40. Mukohara T,Kudoh S,Matsuura K,Yamauchi S,Kimura T,Yoshimura N,Kanazawa H,Hirata K,Inoue K,Wanibuchi H,Fukushima S,Yoshikawa J.Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC.Anticancer Res. 2004;24:11-17.
41. Pandya KJ,Dahlberg S,Hidalgo M,Cohen RB,Lee MW,Schiller JH,Johnson DH.A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).J Thorac Oncol. 2007;2:1036-1041.
42. Pelloski CE,Lin E,Zhang L,Yung WK,Colman H,Liu JL,Woo SY,Heimberger AB,Suki D,Prados M,Chang S,Barker FG,Fuller GN,Aldape KD.Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.Clin Cancer Res. 2006;12:3935-3941.
43. Poste G,Carbone DP,Parkinson DR,Verweij J,Hewitt SM,Jessup JM.Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.Clin Cancer Res. 2012;18:1515-1523.
44. Prevo R,Deutsch E,Sampson O,Diplexcito J,Cengel K,Harper J,O'Neill P,McKenna WG,Patel S,Bernhard EJ.Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.Cancer Res. 2008;68:5915-5923.
45. Ramalingam SS,Owonikoko TK,Behera M,Subramanian J,Saba NF,Kono SA,Gal AA,Sica G,Harvey RD,Chen Z,Klass CM,Shin DM,Fu H,Sun SY,Govindan R,Khuri FR.Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.J Thorac Oncol. 2013;8:369-372.
46. Renshaw J,Taylor KR,Bishop R,Valenti M,De Haven Brandon A,Gowan S,Eccles SA,Ruddle RR,Johnson LD,Raynaud FI,Selfe JL,Thway K,Pietsch T,Pearson AD,Shipley J.Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.Clin Cancer Res. 2013;19:1-12.
47. Rinehart J,Adjei AA,Lorusso PM,Waterhouse D,Hecht JR,Natale RB,Hamid O,Varterasian M,Asbury P,Kaldjian EP,Gulyas S,Mitchell DY,Herrera R,Sebolt-Leopold JS,Meyer MB.Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.J Clin Oncol. 2004;22:4456-4462.
48. Rini BI.Temsirolimus, an inhibitor of mammalian target of rapamycin.Clin Cancer Res. 2008;14:1286-1290.
49. Saini KS,Loi S,de Azambuja E,Metzger-Filho O,Saini ML,Ignatiadis M,Dancey JE,Piccart-Gebhart MJ.Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.Cancer Treat Rev. 2013;39:935-946.
50. Samuels Y,Ericson K.Oncogenic PI3K and its role in cancer.Curr Opin Oncol. 2006;18:77-82.
51. Sasaki H,Endo K,Takada M,Kawahara M,Tanaka H,Kitahara N,Matsumura A,Iuchi K,Kawaguchi T,Okuda K,Kawano O,Yukiue H,Yokoyama T,Yano M,Fujii Y.EGFR polymorphism of the kinase domain in Japanese lung cancer.J Surg Res. 2008;148:260-263.
52. Sawyers CL.Will mTOR inhibitors make it as cancer drugs?.Cancer Cell. 2003;4:343-348.
53. Scartozzi M,Giampieri R,Maccaroni E,Mandolesi A,Biagetti S,Alfonsi S,Giustini L,Loretelli C,Faloppi L,Bittoni A,Bianconi M,Del Prete M,Bearzi I,Cascinu S.Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.J Transl Med. 2012;10:71.
54. Schiller JH.Current standards of care in small-cell and non-small-cell lung cancer.Oncology 61 Suppl. 2001;1:3-13.
55. Schmitz KJ,Wohlschlaeger J,Alakus H,Bohr J,Stauder MA,Worm K,Winde G,Schmid KW,Baba HA.Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations.Virchows Arch. 2007;450:151-159.
56. Schmitz KJ,Wohlschlaeger J,Lang H,Sotiropoulos GC,Malago M,Steveling K,Reis H,Cicinnati VR,Schmid KW,Baba HA.Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.J Hepatol. 2008;48:83-90.
57. Smalley KS,Haass NK,Brafford PA,Lioni M,Flaherty KT,Herlyn M.Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.Mol Cancer Ther. 2006;5:1136-1144.
58. Sonobe M,Nakagawa M,Takenaka K,Katakura H,Adachi M,Yanagihara K,Otake Y,Wada H,Tanaka F.Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.J Surg Oncol. 2007;95:63-69.
59. Suzuki T,Nakagawa T,Endo H,Mitsudomi T,Masuda A,Yatabe Y,Sugiura T,Takahashi T,Hida T.The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.Lung Cancer. 2003;42:35-41.
60. Tamborini E,Virdis E,Negri T,Orsenigo M,Brich S,Conca E,Gronchi A,Stacchiotti S,Manenti G,Casali PG,Pierotti MA,Pilotti S.Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.Neuro Oncol. 2010;12:776-789.
61. Tang JM,He QY,Guo RX,Chang XJ.Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.Lung Cancer. 2006;51:181-191.
62. Taylor CR.The total test approach to standardization of immunohistochemistry.Arch Pathol Lab Med. 2000;124:945-951.
63. Tsurutani J,Steinberg SM,Ballas M,Robertson M,LoPiccolo J,Soda H,Kohno S,Egilsson V,Dennis PA.Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma.Lung Cancer. 2007;55:115-121.
64. Vergis R,Corbishley CM,Norman AR,Bartlett J,Jhavar S,Borre M,Heeboll S,Horwich A,Huddart R,Khoo V,Eeles R,Cooper C,Sydes M,Dearnaley D,Parker C.Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.Lancet Oncol. 2008;9:342-351.
65. Yano S,Wang W,Li Q,Matsumoto K,Sakurama H,Nakamura T,Ogino H,Kakiuchi S,Hanibuchi M,Nishioka Y,Uehara H,Mitsudomi T,Yatabe Y,Nakamura T,Sone S.Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.Cancer Res. 2008;68:9479-9487.
66. Yu K,Toral-Barza L,Shi C,Zhang WG,Zask A.Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy.Cancer Biol Ther. 2008;7:307-315.